168 related articles for article (PubMed ID: 36204895)
1. Hypophysitis: A rare but noteworthy immune-related adverse event secondary to camrelizumab therapy.
Han X; Meng M; Zhang T; Wang J; Huang G; Ni Y; Li W; Dai J; Yang X; Ye X
J Cancer Res Ther; 2022 Sep; 18(5):1440-1443. PubMed ID: 36204895
[TBL] [Abstract][Full Text] [Related]
2. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
3. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer.
Chang J; Tran J; Kamel D; Basu A
BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30850565
[TBL] [Abstract][Full Text] [Related]
5. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.
Sekizaki T; Kameda H; Oba C; Yong Cho K; Nakamura A; Miyoshi H; Osawa T; Shinohara N; Atsumi T
Endocr J; 2019 Oct; 66(10):937-941. PubMed ID: 31217401
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy-Associated Hypophysitis under Anti-PD1: Two Case Reports.
Shen X; Yang M; Xu H; Zhou H; Wang L; Ma J
Endocr Metab Immune Disord Drug Targets; 2023; 23(7):996-1004. PubMed ID: 36503448
[TBL] [Abstract][Full Text] [Related]
8. Salvage therapy of reactive capillary hemangiomas: Apatinib alleviates the unique adverse events induced by camrelizumab in non-small cell lung cancer.
Li W; Wei Z; Yang X; Huang G; Han X; Ni Y; Wang J; Meng M; Zou Z; Wen Q; Ye X
J Cancer Res Ther; 2019; 15(7):1624-1628. PubMed ID: 31939447
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitor-Associated Central Adrenal Insufficiency.
Mishra T; He G; Sreeram K; Rauf M; Subahi A; Hazem M
Am J Ther; 2019; 26(5):e626-e627. PubMed ID: 30277909
[No Abstract] [Full Text] [Related]
10. Nivolumab induced hypophysitis in a patient with recurrent non-small cell lung cancer.
Kajal S; Gupta P; Ahmed A; Gupta A
Drug Discov Ther; 2021 Sep; 15(4):218-221. PubMed ID: 34456195
[TBL] [Abstract][Full Text] [Related]
11. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.
Mishima Y; Fukaishi T; Inase N; Isogai S
Intern Med; 2019 Mar; 58(5):693-697. PubMed ID: 30449786
[TBL] [Abstract][Full Text] [Related]
13. Rechallenge of camrelizumab in non-small-cell lung cancer patients treated previously with camrelizumab and microwave ablation.
Wei Z; Yang X; Ye X
J Cancer Res Ther; 2020 Sep; 16(5):1191-1195. PubMed ID: 33004770
[TBL] [Abstract][Full Text] [Related]
14. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature.
Li L; Lou A; Yu J
Ann Palliat Med; 2021 Jul; 10(7):8460-8466. PubMed ID: 34044548
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
Nada A; Bhat R; Cousins J
Curr Probl Cancer; 2021 Feb; 45(1):100644. PubMed ID: 32888700
[TBL] [Abstract][Full Text] [Related]
17. Hypophysitis secondary to pembrolizumab: a case report and review of the literature.
Montero Pérez O; Sánchez Escudero L; Guzmán Ramos MI; Aviñó Tarazona V
Anticancer Drugs; 2022 Jan; 33(1):94-99. PubMed ID: 34261922
[TBL] [Abstract][Full Text] [Related]
18. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
Shen T; Zheng S; Geng L; Liu Z; Xu J; Lin B; Qian J; Zheng S
Technol Cancer Res Treat; 2020; 19():1533033820979703. PubMed ID: 33308041
[TBL] [Abstract][Full Text] [Related]
19. Anti-PD-1 antibody camrelizumab plus doxorubicin showed durable response in pulmonary sarcomatoid carcinoma: Case report and literature review.
Kong F; Wang W; Gong L; Wu W; Liu Y
J Clin Pharm Ther; 2020 Dec; 45(6):1489-1496. PubMed ID: 32776600
[TBL] [Abstract][Full Text] [Related]
20. Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature.
Liu L; Liu Y; Gong L; Zhang M; Wu W
Cancer Biol Ther; 2020 Nov; 21(11):983-989. PubMed ID: 33092443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
